In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 607-612

  Russo, Andrea L ^a,c   Kwon, Hyuk Chan ^a   Burgan, William E ^b,d   Carter, Donna ^b,d   Beam, Katie ^b,d   Weizheng, Xu ^e   Zhang, Jie ^e   Slushier, Barbara S ^e   Chakravarti, Arnab ^f   Tofilon, Philip J ^g   Camphausen, Kevin ^a,b  

^a Radiation Oncology Branch   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d SAIC FREDERICK INC   (United States)

^e EISAI INC   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E 7016; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL SURVIVAL; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG INHIBITION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; COMET ASSAY; DACARBAZINE; DNA REPAIR; ENZYME INHIBITORS; GLIOBLASTOMA; HUMANS; MICE; MITOSIS; POLY(ADP-RIBOSE) POLYMERASES; RADIOTHERAPY;

EID: 59549097382     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2079     Document Type: Article

References (22)

1. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64:6892-9.
2. Stupp R, Mason W, Van Den Bent M, etal. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
3. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007;13:1383-8.
4. ZarembaT, Curtin NJ. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem 2007;7:515-23.
5. Schreiber V, Dantzer F, Ame J, de Murcia G. Poly-(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7:517-28.
6. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature 1980;283:593-6.
7. Bowman K, White A, Golding B, Griffin R, Curtin N. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer1998;78:1269-77.
8. Liu L, Gerson S. Targeted modulation of MGMT: clinical implications. Clin Cancer Res 2006;12:328-31.
9. Clark J, Ferris G, Pinder S. Inhibition of nuclear NAD nucleosidase and polyADP-ribose polymerase activity from rat liver by nicotinamide and 5'-methyl nicotinamide. Biochem Biophys Acta 1971;238:82-5.
10. Milam K, Cleaver J. Inhibitors of poly(adenosine diphosphate-ribose) synthesis: effect on other metabolic processes. Science 1984;223:589-91.
11. Southan G, Szabo C. Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem 2003;10:321-40.
12. Tentori L, Leonetti C, Scarsella M, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003;9:5370-9.
13. Xu B, Kim ST, Lim DS, Kastan MB. Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol Cell Biol 2002;22:1049-59.
14. Pilch DR, Sedelnikova OA, Redon C, Celeste A, Nussenzweig A, Bonner WM. Characteristics of γ-H2AX foci at DNA double-strand breaks sites. Biochem Cell Biol 2003;81:123-9.
15. Banath J, Olive P. Expression of phosphorylated his-tone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 2003;63:4347-50.
16. Ueno A. Tanaka O, Matsudaira H. Inhibition of γ-ray dose-rate effects by D20 and inhibitors of poly(ADP-ribose) synthetase in cultured mammalian L5178Y cells. Radiat Res 1984;98:574-82.
17. Thraves P, Mossman K, Brennan T, Dritschilo A. Radiosensitization of human fibroblasts by 3-amino-benzamide: an inhibitor of poly(ADP-ribosylation). RadiatRes1985;104:119-27.
18. Kelland L,Tonkin K. The effect of 3-aminobenza-mide in the radiation response of three human cervix carcinoma xenografts. Radiother Oncol 1989;15:363-9.
19. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67.
20. Liu S, Coackley C, Krause M, Jalali F, Chan N, Bristow R. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol 2008;88:258-68. Epub 2008 May 2.
21. Albert JM, Cao C, Kim KW, et al. Inhibition of poly-(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007;13:3033-42.
22. Brock W, Milas L, Bergh S, Lo R, Szabo C, Mason K. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett 2004;205:155-60.